Abbott
India’s NPPA identifies 634 non-compliant drug pricings
February 24, 2017Medical Communications, Sales and Marketing Abbott, AstraZeneca, Cipla, Dr Reddy's, Dr Reddy’s, nppa
India’s National Pharmaceutical Pricing Authority (NPPA) has revealed that as many as 634 drugs from top pharma firms in the …
FDA warns that St. Jude’s heart devices could be hacked
January 11, 2017Medical Communications, Research and Development Abbott, Muddy waters, St. Jude, medsec
The FDA regulator has publicly announced that there are safety issues with certain of St. Jude’s medical devices, including cardiac …
Abbott completes $25 billion deal for St. Jude
January 9, 2017Sales and Marketing Abbott, St. Jude
It has been announced that the Federal Trade Commission has approved Abbott Laboratories acquisition of St. Jude Medical for $25 …
Abbott-St. Jude $25 billion deal close to clearance
November 16, 2016Research and Development, Sales and Marketing Abbott, St. Jude, acquisition
EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
J&J in $4.33bn eye surgery unit acquisition
September 19, 2016Manufacturing and Production, Sales and Marketing Abbott, Johnson & Johnson, acquisition
Johnson & Johnson has agreed to buy Abbott Laboratories’ eye surgery equipment unit in an all-cash deal for £4.33 billion …
FDA approves first extended depth of focus lenses for people with cataracts
July 18, 2016Research and Development, Sales and Marketing Abbott, FDA, cataracts
Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …
Abbott to purchase St Jude Medical in $25 billion deal
April 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing $25, 25 billion, Abbott, Medical device, acquisition, purchase, st jude medical
Abbott (NYSE: ABT) has announced an agreement to purchase device manufacturer, St Jude Medical, in a deal worth $25 billion. …
FDA says benefits outweigh risks in Abbott’s heart stent, Absorb
March 16, 2016Research and Development, Sales and Marketing Abbott, absorb, bioresorbable, coronary artery disease
An independent panel convened by the US Food and Drug Administration (FDA) has unanimously voted that the benefits of Absorb, …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Mylan buys into women’s health
February 3, 2015Sales and Marketing Abbott, FDA, India, Mylan, famy care, female, women
Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 …
GSK-Novartis mega-deal signed-off by EC
January 29, 2015Research and Development, Sales and Marketing Abbott, GSK, Mylan, Novartis, acquisition, etc, merger
The European Commission has approved a GSK-Novartis M&A deal, in which GSK will purchase Novartis’ vaccines unit and Novartis will …
Abbott buys Russian firm Veropharm
December 15, 2014Manufacturing and Production, Sales and Marketing Abbott, Fresenius, cfr pharma, petrovax, sistema, veropharm, zenitco
Abbott has completed its purchase of Russia-based Veropharm in a $305 million deal as it looks to firmly establish itself …
Mylan shells out $32.5m to cover tax inversion fines
December 11, 2014Sales and Marketing AbbVie, Abbott, Mylan, SEC, bresch, coury
Mylan will pay five of its top executives an early $32.5 million to cover penalties from the company’s plans to …
AbbVie financials beat expectations
October 31, 2014Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
